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year saved, $39 per QALY and $37 per DALY averted. CONCLUSIONS: For pregnant,
HIV-1 infected women presenting at delivery and not requiring antiretrovirals for
their own health, infant NVP throughout breastfeeding is likely to be considered
cost-effective. For those presenting antenatally, antenatal ZDV followed by infant
NVP throughout breastfeeding (WHO Option A) is likely to be considered cost-
effective.
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OBJECTIVES: To provide pharmacoeconomic evaluation of diagnostics of tubercu-
losis infection (TI) with Allergen tuberculosis recombinant (CFP10-ESAT6) and Al-
lergen tuberculosis purified liquid in the standard dilution for intradermal use (PPD
RT 23 SSI). METHODS: The cost-effectiveness analysis. In the study direct costs
included cost of TI diagnostics, cost of the additionally surveys, cost of observation
in the clinic and cost of treatment of TI patients. RESULTS: The efficacy of TI
diagnostics was evaluated. The frequency of diagnostics of active tuberculosis has
been evaluated on the data of the TI diagnostics in children and adolescents in
Moscow and Samara region. The proportion of patients with active tuberculosis
were 0.31%, 0.006% and 0.04% for CFP10-ESAT6, PPD RT 23 SSI and a combined
scheme of diagnostics (simulate situation when both drugs use), respectively. Di-
rect costs for TI diagnostics, surveillance and treatment of TI were calculated.
Direct costs amounted to 380.36 RUB (9.17 EUR), 218.18 RUB (5.26 EUR) and 220.46
RUB (5.31 EUR) for CFP10-ESAT6, PPD RT 23 SSI and combination scheme, on one
patient, respectively. Finally, total direct costs for the diagnostics one patient with
active tuberculosis were 122.687 RUB (2.956 EUR), 3.646.833 RUB (87.875 EUR) and
551.150 RUB (13.281 EUR), for the estimated diagnostic schemes, respectively.
CONCLUSIONS: The pharmacoeconomic study results shows, that CFP10-ESAT6 is
dominant technology from “cost-effectiveness” analysis perspective.
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OBJECTIVES: To highlight the different results obtained when conducting an eco-
nomic evaluation of RPV using response rates other than those in the SmPC.
METHODS: We considered the overall response rate of Rilpivirine (RPV) clinical
trials, and the response rates in the indicated population based on its SmPC (pa-
tients with baseline viral load  100.000 copies/ml). Efficacy was defined as the
percentage of patients having viral load  50 copies/ml at week 48 per intention-
to-treat analysis. The analysis perspective is that of the Spanish NHS, considering
in our model only the cost of the antiviral drug. Time horizon is 48 weeks and costs
are ex-factory prices (2012). Since the reimbursed price of RPV has not being ap-
proved in Spain yet, our base case assumes the hypothesis anticipated by some
Spanish HTAs that RPV could be priced as parity to the SoC, Efavirenz (EFV). Four
scenarios were performed: price parity, 2.5%, 5% and 7.5% premium price over
EFV.RESULTS: In the price parity scenario, depending on the response rate applied,
the cost per responder of RPV ranges from 3.575€ (SmPC efficacy rates) to 3.839€
(overall efficacy rates). It is estimated that HIV-1 incidence in Spain is around 2,600
new patients/year, 70% of whom would have baseline VL  100.000 copies/ml. In
the price parity scenario, since the difference in efficacy rates is 6.6% (1.6%; 11.5%)
IC 95% RPV vs EFV, initiating the treatment with RPV instead of EFV would allow to
successfully treat 120 patients more than with EFV.CONCLUSIONS: Economic eval-
uation should be conducted using response rates associated to the approved prod-
uct label to get the most accurate measure of true value. When doing so, our model
demonstrates that RPV would be more cost-effective than EFV in naïve patients
with baseline VL  100.000 copies/ml in the four scenarios analyzed.
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OBJECTIVES: Hepatitis C is an infection that when left untreated or unsuccessfully
treated, progresses into Advanced Liver Disease (ALD) associated with a high clin-
ical, humanistic and economic burden. Due to limited economic resources, health
care providers may have to choose whether to treat F2 patients with PR alone vs.
Telaprevir plus PR (TPR). This publication aims to demonstrate the clinical and
economic value of treating naïve F2 patients with TPR, a triple based regimen
compared to PR alone. METHODS: A post-hoc analysis of the phase III ADVANCE
was conducted and NNT were calculated. Cost-effectiveness of TPR vs. PR in F2
patients was determined based on a UK economic model. A cost per cure (SVR)
model analyzed the number of cured patients with TPR vs PR and number of pa-
tients treated but not cured. RESULTS: NNT in F2 patients was estimated to be 3.3.
In previously untreated F2 fibrosis patients, TPR was associated with higher costs
and improved outcomes compared to PR with an Incremental Cost Effectiveness
Ratio (ICER) of £ 9,930/ QALY. Treating 100 F2 patients with TPR results in 79 cured
patients compared with only 49 cured patients with PR. In order to achieve cure in 50
patients, 13 patients would be treated but not cured with TPR compared to 52 treated but
not cured with PR alone. With a million £ investment with TPR only 7 patients are not
cured compared to 53 patients with PR alone. CONCLUSIONS: TPR provides clinical
and economic value for F2 untreated patients. It is clinically superior treatment
versus PR, is a cost-effective treatment option and within a fixed budget choosing
TPR instead of PR results in more patients cured and in less treatment failures.
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OBJECTIVES: Invasive pneumococcal disease (IPD) is a major public health chal-
lenge. Pediatric high-risk population (PHR) (like sickle cell disease, HIV infected or
those receiving immunosuppressive medications) are 30-100 times more likely to
develop IPD compared to healthy children. This study aims to perform cost-effec-
tiveness analysis of 13-valent pneumococcal vaccine (PCV13) in PHR, from a public
payer perspective in Brazil. METHODS: A decision tree-model was developed to
simulate IPD outcomes in PHR after vaccination with PCV13 versus PCV10 and
non-vaccination and their associated direct costs in a 10-year time horizon. Despite
comparison with PCV10, this indication is off-label in Brazil and no studies are
available to this population segment. Effectiveness parameters are avoided cases
of IPD, hospitalized and non-hospitalized pneumonia. Direct medical costs in-
cluded hospital days, medical personnel time, outpatient visits, diagnostic tests
and medications. Clinical data and costs were extracted from literature, presented
in 2012 USD. Probabilistic sensitivity analyses were performed trough Monte Carlo
Simulation second-order approach. RESULTS: For a 611,737 patients cohort, PCV13
avoided [1,626; 1,851] IPD, [1,996; 92,805] hospitalized pneumonia, [1,585; 73,700]
non-hospitalized pneumonia, and [570; 649] IPD deaths, versus [PCV10; non-vacci-
nation]. Projected treatment costs for PCV13 versus PCV10 were 703,326,000USD,
and 707,410,000USD, respectively. For PCV13 versus non-vaccination projected
treatment costs was 367,000,000USD versus 705,000,000USD, respectively. In cost-
effectiveness analysis, PCV13 was cost-saving in all comparisons. CONCLUSIONS:
From the public payer perspective in Brazil, PCV13 showed to be dominant regard-
ing life years gained than PCV10 vaccination and non-vaccination strategy.
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OBJECTIVES: To estimate the cost per sustained virological response (SVR) in ge-
notype 1 (G1) hepatitis C (HCV) patients according to previous treatment response
and METAVIR groups in Brazil. METHODS: SVR and extended rapid virological
response (eRVR) rates were from the respective phase III clinical trials of telaprevir
(ADVANCE and REALIZE) and boceprevir (SPRINT-2 and RESPOND-2) for treatment
naive patients, METAVIR F0-F3 naive patients, and treatment experienced patients
(relapsers, partial responders and null responders). When SVR and eRVR rates were
not available for a patient subgroup these were assumed to be the same as the
global patient population. Brazilian treatment costs were based on the eRVR rates
and calculated based on the prices for telaprevir and boceprevir recently published
by the HTA body CONITEC. Treatment costs for pegylated interferon and ribavirin
were calculated from the reimbursed price published in the official website:
www.comprasnet.gov.br. RESULTS: Telaprevir has the lowest cost-SVR for all pa-
tients in the analysis compared to boceprevir. In treatment naive patients, telapre-
vir has a cost-SVR of R$ 64.513 compared to boceprevir with R$ 72.275. In METAVIR
scale of F0-F3 treatment naive patients, telaprevir has a lower cost-SVR of R$
64.196, while the cost-SVR for boceprevir remains 12% higher (R$ 72.275). The low-
est cost-SVR was observed for the prior relapse patients treated with telaprevir, R$
51.283/SVR, compared to boceprevir with R$ 58.736/SVR. Boceprevir has the highest
cost-SVR at R$ 90.658 compared to R$68.144 with telaprevir for patients with a
previous partial response. For prior null-responders, telaprevir is the only option
since as these patients were not studied with boceprevir. CONCLUSIONS: Telapre-
vir has the lowest cost-SVR compared to boceprevir for the treatment of hepatitis C
G1 patients in Brazil regardless of baseline disease severity and prior treatment
response.
PIN59
COST-EFFECTIVENESS OF AMOXICILLIN CLAVULANATE DIRECTED TOWARDS
THE APPLICATION OF INDICATED AT PRIMARY CARE IN THE TREATMENT OF
COMMUNITY ACQUIRED PNEUMONIA, ACUTE RHINOSINUSITIS,
TONSILLOPHARYNGITIS, AND ACUTE OTITIS MEDIA
Malhan S1, Oksuz E2, Eray O3, Koc E4
1Baskent University, Anakara, Turkey, 2Baskent University, Ankara, Turkey, 3GlaxoSmithKline,
Istanbul, Turkey, 4GlaxoSmithKline, Istanbul, Turkey
OBJECTIVES: To assess the cost-effectiveness of amoxicillin clavunate compared
to amoxicillin at primary care level in Turkey for community acquired pneumonia,
acute rhinosinusitis, tonsillopharyngitis, and acute otitis media. METHODS: As
proposed by the guidelines for the treatment of diseases costs have been deter-
mined through applying cost of illness methodology. The agents have been calcu-
lated by evaluating all brands and forms over continuous doses. The perspective of
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